Table 3.
Disease status at the end of followup.
| Variable | rhTSH group (n = 18) | THW group (n = 27) | P |
|---|---|---|---|
| Postablation followup, months, mean ± SD | 40 ± 16 | 54 ± 40 | 0.02 |
|
| |||
| Disease statusa at the end of followup, % (n) | |||
| NED | 72% (13) | 59% (16) | 0.03 |
| Persistent disease | 22% (4) | 33% (9) | 0.03 |
| Recurrent disease | 6% (1) | 7% (2) | NS |
|
| |||
| Sites of persistent disease, n | |||
| Local | 0 | 2 | Not tested |
| Lymph nodes | 1 | 3 | |
| Unknown (biochemical only)b | 3 | 4 | |
|
| |||
| Sites of recurrence, n | |||
| Local | 0 | 0 | Not tested |
| Lymph nodes | 1 | 2 | |
| Unknown (biochemical only)b | 0 | 0 | |
NED: no evidence of disease; rhTSH: recombinant human thyroid-stimulating hormone; SD: standard deviation; THW: thyroid hormone withdrawal or withholding.
aPlease refer to “Materials and Methods” section for a description of potential disease states.
bRefers to elevated stimulated Tg (>2 μg/L) without structural evidence of disease.